Hans-Peter Volz Selected Research

lavender oil

3/2022	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
1/2018	Silexan in anxiety disorders: Clinical data and pharmacological background.
1/2017	Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set.
2/2016	Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial.
6/2014	Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
12/2010	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
9/2010	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Peter Volz Research Topics

Disease

8	Anxiety Disorders (Anxiety Disorder) 03/2022 - 09/2010
6	Major Depressive Disorder (Major Depressive Disorders) 07/2022 - 03/2002
3	Psychotic Disorders (Schizoaffective Disorder) 12/2005 - 05/2003
2	Depressive Disorder (Melancholia) 03/2022 - 01/2006
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2018 - 07/2013
2	Bipolar Disorder (Manic Depressive Psychosis) 08/2009 - 12/2005
2	Schizophrenia (Dementia Praecox) 04/2007 - 03/2002
2	Somatoform Disorders (Somatoform Disorder) 08/2003 - 11/2002
2	Mood Disorders (Mood Disorder) 05/2003 - 05/2003
2	Thyroiditis 05/2003 - 05/2003
1	Catatonia 04/2021
1	Mental Disorders (Mental Disorder) 01/2017
1	Hepatitis 01/2017
1	Eructation (Eructations) 02/2016
1	Psychomotor Agitation (Akathisia) 12/2010
1	Syndrome (Syndromes) 07/2010
1	Mitochondrial Diseases (Mitochondrial Disease) 08/2009
1	Treatment-Resistant Depressive Disorder 04/2009
1	Corpus callosum agenesis neuronopathy 12/2005
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2005

Drug/Important Bio-Agent (IBA)

7	lavender oilIBA 03/2022 - 09/2010
4	Antidepressive Agents (Antidepressants)IBA 07/2022 - 04/2009
4	Anti-Anxiety Agents (Anxiolytics)IBA 03/2022 - 08/2003
3	Antipsychotic Agents (Antipsychotics)IBA 04/2021 - 04/2007
3	Pharmaceutical PreparationsIBA 04/2021 - 08/2009
2	Paroxetine (Paxil)FDA LinkGeneric 06/2014 - 07/2010
2	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 09/2009 - 04/2009
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 09/2009 - 04/2009
2	Peroxidase (Myeloperoxidase)IBA 05/2003 - 05/2003
2	AntibodiesIBA 05/2003 - 05/2003
2	Thyrotropin Receptors (Thyrotropin Receptor)IBA 05/2003 - 05/2003
2	SteroidsIBA 05/2003 - 05/2003
1	Aripiprazole (Abilify)FDA Link 04/2021
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 04/2021
1	agomelatine (S20098)IBA 01/2017
1	Lorazepam (Ativan)FDA LinkGeneric 12/2010
1	LithiumIBA 08/2009
1	Fluoxetine (Prozac)FDA LinkGeneric 04/2009
1	Citalopram FDA LinkGeneric 04/2009
1	Bupropion (Wellbutrin)FDA LinkGeneric 04/2009
1	Sertraline (Zoloft)FDA LinkGeneric 04/2009
1	Phospholipids (Phosphatides)FDA LinkGeneric 04/2007
1	SymportersIBA 12/2005
1	Potassium Chloride FDA LinkGeneric 12/2005
1	OpipramolIBA 08/2003
1	Psychotropic Drugs (Psychoactive Drugs)IBA 08/2003
1	Hypericum extract LI 160IBA 11/2002
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 03/2002
1	N 30IBA 03/2002

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2017
1	Secondary Prevention 04/2009
1	Drug Therapy (Chemotherapy) 01/2006